Related Experiment Video
Updated: Feb 21, 2026

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
Vedolizumab-Associated Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder in a Biologic-Naïve
Romina Garakani1,2, Zane Sejdiu1,2, Devon Cross2
1Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Abstract:
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-TCLPD) is a rare lymphoproliferative disorder that is occasionally diagnosed in children and adolescents. We present a case of PCSM-TCLPD in an 11-year-old female with biologic-naïve Crohn's disease well-controlled on vedolizumab, which was initiated 12 months prior to lesion appearance. We propose that vedolizumab may have played a role in the development of PCSM-TCLPD.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Ulcerative Colitis in IBD

